NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage
Globe Newswire•30/10/2026•09:10 ET
1
Key Highlights
- ➤500-patient pivotal trial planned across 30 hospitals in three countries
- ➤NEO100 uses intranasal delivery designed to bypass the blood-brain barrier
- ➤Six of 25 patients showed significant radiographic remission in December 2025 update
- ➤NEO212 completed Phase 1; FDA meeting scheduled November 17 on potential Phase 2
- ➤Approximately 877,000 NTHI shares reported short as of October 15
Expert Statements
Dr. Wallace, Physician
“We can't see it, actually, at this moment.”
DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- (247MarketNews.com) — In a market where the latest whizbang trends often dominate investor attention, NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing something considerably more meaningful: advancing potential treatments for some of the most difficult-to-treat brain cancers while building a clinical development program that could eventually reach hundreds of patients internationally.
Now, the company is putting some impressive numbers behind that ambition.
Get started
Create a free account to read the full story.